Cefuroxime: Dosing, Contraindications, and Adverse Effects
Cefuroxime is an effective second-generation cephalosporin with proven efficacy for respiratory, skin/soft tissue, urinary tract, and early Lyme disease infections, dosed as 500 mg twice daily orally (cefuroxime axetil) for 14 days in most adult infections, or 750 mg to 1.5 grams every 8 hours intravenously for more severe infections.
Adult Dosing Recommendations
Oral Formulation (Cefuroxime Axetil)
- Standard infections (respiratory tract, skin/soft tissue, uncomplicated UTI): 500 mg twice daily for 14 days 1, 2
- Early Lyme disease: 500 mg twice daily for 14-21 days 1
- Mild UTI: 125 mg twice daily may be effective 3
- Uncomplicated gonorrhea: 1 gram single dose (though not first-line) 4
The oral formulation achieves maximum plasma concentrations of 7.9 mg/L after 500 mg dosing, with 68% bioavailability when taken with food 3. Take with food to optimize absorption.
Parenteral Formulation (Cefuroxime Sodium)
- Uncomplicated infections (UTI, skin/soft tissue, pneumonia): 750 mg IV/IM every 8 hours 2
- Severe/complicated infections: 1.5 grams IV every 8 hours 2
- Life-threatening infections: 1.5 grams every 6 hours 2
- Bacterial meningitis: Up to 3 grams every 8 hours (maximum dose) 2
- Bone/joint infections: 1.5 grams every 8 hours 2
Duration: Continue for minimum 48-72 hours after symptom resolution or bacterial eradication; minimum 10 days for Streptococcus pyogenes infections 2
Renal Dose Adjustments
Mandatory dose reduction in renal impairment 2:
- CrCl >20 mL/min: 750 mg-1.5 grams every 8 hours
- CrCl 10-20 mL/min: 750 mg every 12 hours
- CrCl <10 mL/min: 750 mg every 24 hours
- Post-hemodialysis: Give additional dose after dialysis
Pediatric Dosing (>3 months)
- Standard infections: 50-100 mg/kg/day divided every 6-8 hours 2
- Severe infections: 100 mg/kg/day (not exceeding adult maximum) 2
- Bone/joint infections: 150 mg/kg/day divided every 8 hours 2
- Bacterial meningitis: 200-240 mg/kg/day IV divided every 6-8 hours 2
For oral cefuroxime axetil: 30 mg/kg/day in 2 divided doses (maximum 500 mg per dose) 1
Clinical Efficacy Profile
Cefuroxime demonstrates excellent activity against common respiratory pathogens including Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase producers), Moraxella catarrhalis, and methicillin-sensitive Staphylococcus aureus 3, 5, 6.
Key efficacy data:
- Achieves 40% time above MIC for pathogens with MIC ≤0.5 mg/L at standard 500 mg twice daily dosing 7
- Probability of target attainment ≥90% for MICs up to 0.5 mg/L with tablets, up to 1.0 mg/L with oral suspension 7
- For UTI: 100% target attainment for MICs up to 8 mg/L due to high urinary concentrations 7
In comparative trials for chronic rhinosinusitis, cefuroxime 500 mg twice daily showed equivalent clinical cure rates to amoxicillin-clavulanate, though amoxicillin-clavulanate demonstrated faster symptom improvement at days 3-5 and lower relapse rates (0% vs 8%, p=0.0049) 8. This suggests amoxicillin-clavulanate may be preferred for rhinosinusitis when both are options.
Contraindications
Absolute contraindications:
- Known hypersensitivity to cefuroxime or other cephalosporins
- History of severe immediate hypersensitivity (anaphylaxis) to any β-lactam antibiotic
Relative contraindications:
- Pregnancy: Avoid doxycycline; cefuroxime is acceptable for Lyme disease in pregnant patients 1
- Penicillin allergy: Cross-reactivity risk is 2.11% for cefuroxime (low R1 side chain similarity) 9. Skin testing not routinely required but consider for patients with multiple drug allergies 9
Adverse Effects
Common (Mild-Moderate)
- Gastrointestinal disturbances: Most frequent adverse event, including diarrhea, nausea, vomiting 3, 5, 6
- Generally mild, transient, and reversible upon discontinuation 3
Serious (Rare but Important)
Based on pharmacovigilance data from JADER and FAERS databases 10, 11:
Immune-mediated reactions:
- Anaphylactic shock: Stronger signal in FAERS database; more common with injectable formulations 10, 11
- Stevens-Johnson syndrome: Identified in both databases 10
- Oculomucocutaneous syndrome: Newly identified signal in JADER database 10
Hepatobiliary disorders:
- Drug-induced liver injury: Stronger signal in JADER database 10
- Jaundice: Stronger signal in JADER database 10
Formulation-specific risks 11:
- Injectable formulations: Higher risk of hypotension and anaphylactic shock compared to tablets
- Intraocular administration: Significant risk of eye disorders; use only prescribed 0.1 mL of 1% solution for endophthalmitis prophylaxis 12. Improper dilution or excessive dosing causes permanent ocular damage 12
Monitoring Recommendations
Enhanced monitoring warranted for:
- Skin and subcutaneous tissue disorders
- Immune system disorders
- Hepatobiliary disorders 10
Clinical Pearls and Pitfalls
Common pitfalls to avoid:
- First-generation cephalosporins (cephalexin) are ineffective for Lyme disease and should never be substituted 1
- Do not use shorter than 14-day courses for β-lactams in early Lyme disease (unlike doxycycline which can be 10 days) 1
- Cefuroxime is inferior to amoxicillin-clavulanate for acute otitis media treatment failures 13
- Not recommended for pediatric gonorrhea due to inadequate evaluation in children 4
- Intraocular use requires exact dilution: Only 0.1 mL of 1% solution; errors cause permanent damage 12
When to choose cefuroxime over alternatives:
- Patient took amoxicillin in previous 30 days (for respiratory infections) 13
- β-lactamase-producing H. influenzae or M. catarrhalis suspected 14
- Penicillin allergy with low cross-reactivity risk 9
- Sequential IV-to-oral therapy for community-acquired pneumonia 5, 6
When NOT to use cefuroxime:
- Macrolides preferred over cefuroxime for atypical pneumonia coverage
- Amoxicillin-clavulanate preferred for rhinosinusitis (faster response, lower relapse) 8
- Drug-resistant S. pneumoniae suspected (consider respiratory fluoroquinolones)